Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans

被引:63
作者
Iwasaki, T
Kondo, K
Kuroda, T
Moritani, Y
Yamagata, S
Sugiura, M
Kikkawa, H
Kaminuma, O
Ikezawa, K
机构
[1] Lead Optimization Res. Laboratory, Tanabe Seiyaku Company, Ltd., Yodogawa, Osaka 532, 3-16-89, Kashima
[2] Lead Optimization Res. Laboratory, Tanabe Seiyaku Company, Ltd., Toda, Saitama 335, 2-2-50, Kawagishi
关键词
D O I
10.1021/jm9509096
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans have been synthesized and evaluated for their ability to selectively inhibit PDE IV isolated from guinea pig. Replacement of the 1-phenyl ring by a pyridone ring led to marked improvement of their selectivity for PDE IV over PDE III. The compounds that were most potent and selective involved those bearing an N-alkylpyridone ring at C-1. These compounds also showed potent antispasmogenic activity without causing significant changes in heart rate in. the guinea pig. The most potent compound was 6,7-diethoxy-2,3-bis(hydroxymethyl)-1-[1-(2-methoxyethyl)-2-oxo-pyrid-4-yl]naphthalene (17f), ED(50) values of histamine-induced and antigen-induced bronchoconstriction in the guinea pig being 0.08 and 2.3 mg/kg iv, respectively. This compound was chosen as a candidate for further pharmacological evaluation.
引用
收藏
页码:2696 / 2704
页数:9
相关论文
共 25 条
[1]   SELECTIVE TYPE-IV PHOSPHODIESTERASE INHIBITORS AS ANTIASTHMATIC AGENTS - THE SYNTHESES AND BIOLOGICAL-ACTIVITIES OF 3-(CYCLOPENTYLOXY)-4-METHOXYBENZAMIDES AND ANALOGS [J].
ASHTON, MJ ;
COOK, DC ;
FENTON, G ;
KARLSSON, JA ;
PALFREYMAN, MN ;
RAEBURN, D ;
RATCLIFFE, AJ ;
SOUNESS, JE ;
THURAIRATNAM, S ;
VICKER, N .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (11) :1696-1703
[2]   PRIMARY SEQUENCE OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES AND THE DESIGN OF SELECTIVE INHIBITORS [J].
BEAVO, JA ;
REIFSNYDER, DH .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (04) :150-155
[3]   CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES - FUNCTIONAL IMPLICATIONS OF MULTIPLE ISOFORMS [J].
BEAVO, JA .
PHYSIOLOGICAL REVIEWS, 1995, 75 (04) :725-748
[4]  
CHRISTENSEN SB, 1994, ANNU REP MED CHEM, V29, P185
[5]   PHOSPHODIESTERASE TYPE-IV INHIBITION - STRUCTURE-ACTIVITY-RELATIONSHIPS OF 1,3-DISUBSTITUTED PYRROLIDINES [J].
FELDMAN, PL ;
BRACKEEN, MF ;
COWAN, DJ ;
MARRON, BE ;
SCHOENEN, FJ ;
STAFFORD, JA ;
SUH, EM ;
DOMANICO, PL ;
ROSE, D ;
LEESNITZER, MA ;
BRAWLEY, ES ;
STRICKLAND, AB ;
VERGHESE, MW ;
CONNOLLY, KM ;
BATEMANFITE, R ;
NOEL, LS ;
SEKUT, L ;
STIMPSON, SA .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (09) :1505-1510
[6]   PROSPECTS FOR SELECTIVE CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF BRONCHIAL-ASTHMA [J].
GIEMBYCZ, MA ;
DENT, G .
CLINICAL AND EXPERIMENTAL ALLERGY, 1992, 22 (03) :337-344
[7]  
HEASLIP RJ, 1991, J PHARMACOL EXP THER, V257, P741
[8]  
HOOD WB, 1989, AM J CARDIOL, V63, P46
[9]  
JOHNSON WS, 1951, ORG REACTIONS, V6, P1
[10]  
KATADA R, 1997, J PHARM SOC JPN, V67, P51